TGS: MANDATORY NOTIFICATION OF TRADE
Oslo, Norway (1 March 2025) – TGS has issued an award of 15,000 Restricted Share Units (RSUs) to Carel Hooijkaas in accordance with the terms of his employment agreement, as…
NIO Inc. Provides February 2025 Delivery Update
13,192 vehicles were delivered in February 2025, increasing by 62.2% year-over-year27,055 vehicles were delivered year-to-date in 2025, increasing by 48.8% year-over-yearCumulative deliveries reached 698,619 as of February 28, 2025 SHANGHAI,…
Monument publie les résultats financiers de son deuxième trimestre 2025
VANCOUVER, Province de Colombie-Britannique, 01 mars 2025 (GLOBE NEWSWIRE) -- Monument Mining Limited (TSX-V : MMY et FSE : D7Q1), ci-après « Monument » ou la « Société », publie…
Verb to Acquire AI Social Selling Startup LyveCom
LOS ALAMITOS, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Verb Technology Company, Inc. (Nasdaq: VERB) ("VERB" or the "Company"), the technology company behind MARKET.live, a leading livestream social shopping platform,…
Form 8.3 – Warehouse REIT Plc
8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full…
Monument veröffentlicht Finanzergebnisse für das zweite Quartal 2025
VANCOUVER, British Columbia, March 01, 2025 (GLOBE NEWSWIRE) -- Monument Mining Limited (TSX-V: MMY und FSE: D7Q1) „Monument“ oder das „Unternehmen“ gab heute seine Finanzergebnisse für die drei Monate („Q2…
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger
All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating…
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS) (“Alumis”) and ACELYRIN, INC. (Nasdaq: SLRN) (“ACELYRIN”) today reaffirmed their commitment to merge…
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq:…
Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
REDWOOD CITY, Calif., March 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting…